The field of lung cancer has undergone another revolution. Following the advent of immunotherapy and checkpoint inhibitors, following the continued expansion of targeted therapies to include ALK, EGFR, ROS1, BRAF, and NTRK, the latest revolution in lung cancer is the combination of the Winter Lung and Miami Lung Cancer Conferences®.

This year will be a year of firsts, even as we enter our 16th year at Winter Lung. I am so excited to be joined again by Mark A. Socinski, MD, of the Florida Hospital Cancer Institute and to team up with Heather A. Wakelee, MD, from Stanford University Medical Center, and Julie R. Brahmer, MD, from Sidney Kimmel Cancer Center at Johns Hopkins who have steadfastly led Miami Lung.

Patients with cancer have the best outcomes when doctors collaborate. The benefits of a multidisciplinary team consisting of medical oncologists, surg oncs, rad oncs, pathologists, PAs, NPs, and nurses is obvious. This year, we take extend that philosophy to CME.

The collaboration of Winter Lung and Miami Lung, through the help of Physicians’ Education Resource®, LLC (PER®) will be the most cutting-edge and practice-focused CME meeting in lung cancer. The established format of Winter Lung’s fast didactic lectures in combination with Miami Lung’s dynamic Medical Crossfire® debates is going to create a truly unique meeting.

I can’t wait for this year’s meeting in Miami, to collaborate further, and for you to join us!

Sincerely,

Rogerio C. Lilenbaum, MD